Scarica l'app Stockscreener
134.28
1.68%
2.22
Dopo l'orario di chiusura:
134.06
-0.22
-0.16%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$132.06
Aprire:
$131.8
Volume 24 ore:
4.98M
Relative Volume:
0.77
Capitalizzazione di mercato:
$233.71B
Reddito:
$43.11B
Utile/perdita netta:
$13.98B
Rapporto P/E:
16.83
EPS:
7.98
Flusso di cassa netto:
$6.78B
1 W Prestazione:
+5.49%
1M Prestazione:
+0.69%
6M Prestazione:
+4.04%
1 anno Prestazione:
+22.34%
Intervallo 1D:
$131.75
$134.71
Intervallo di 1 settimana:
$127.45
$134.71
Portata 52W:
$107.11
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Nome
Abbott Laboratories
Settore
Industria
Telefono
(224) 667-6100
Indirizzo
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Confronta ABT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
134.28 | 227.88B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.14 | 152.55B | 18.49B | 2.51B | 3.23B | 1.68 |
|
SYK
Stryker Corp
|
377.58 | 143.34B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.88 | 114.49B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.35 | 46.11B | 5.69B | 4.14B | 577.90M | 6.96 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-18 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-06-16 | Iniziato | Leerink Partners | Market Perform |
| 2024-10-08 | Iniziato | Oppenheimer | Outperform |
| 2024-09-19 | Iniziato | Piper Sandler | Overweight |
| 2024-07-30 | Downgrade | Edward Jones | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2023-07-21 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Reiterato | Barclays | Overweight |
| 2023-04-20 | Reiterato | Bernstein | Outperform |
| 2023-04-20 | Reiterato | JP Morgan | Overweight |
| 2023-04-20 | Reiterato | Raymond James | Outperform |
| 2023-04-20 | Reiterato | UBS | Buy |
| 2023-04-20 | Reiterato | Wolfe Research | Underperform |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2022-10-26 | Iniziato | Mizuho | Neutral |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-06 | Iniziato | Wolfe Research | Underperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-01-27 | Reiterato | Credit Suisse | Outperform |
| 2022-01-27 | Reiterato | Morgan Stanley | Overweight |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | UBS | Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-10-27 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Iniziato | Redburn | Neutral |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-01-28 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Outperform |
| 2020-06-01 | Downgrade | Goldman | Neutral → Sell |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-06-13 | Reiterato | BofA/Merrill | Buy |
| 2019-02-07 | Reiterato | BofA/Merrill | Buy |
| 2019-01-02 | Downgrade | Citigroup | Neutral → Sell |
| 2018-11-30 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-16 | Iniziato | Barclays | Overweight |
| 2018-06-27 | Iniziato | Bernstein | Outperform |
| 2018-01-30 | Reiterato | Citigroup | Neutral |
| 2018-01-25 | Reiterato | Stifel | Buy |
| 2018-01-25 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Iniziato | Evercore ISI | Outperform |
| 2018-01-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-19 | Reiterato | Stifel | Buy |
Mostra tutto
Abbott Laboratories Borsa (ABT) Ultime notizie
Precision Trading with Abbott Laboratories (ABT) Risk Zones - news.stocktradersdaily.com
Abbott's EPD Growth Beats Market Trends: Here's How to Play the Stock - MSN
How Abbott Laboratories (ABT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Abbott Laboratories Q2 Earnings: Dividends Don’t Lie (NYSE:ABT) - Seeking Alpha
Do New Glucose Monitoring Launches Signal Sustainable Profit Growth for Abbott (ABT)? - simplywall.st
Abbott Laboratories shares rise 1.11% intraday as Senseonics Holdings, Inc. reports Q2 revenue up 37%. - AInvest
Struggling US healthcare stocks endure rough 2025 but draw some bargain hunters - Reuters
Abbott launches next-gen MitraClip, TriClip G5 systems - MassDevice
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - MSN
Abbott Laboratories' Earnings Raise Concerns Despite Strong Profit Numbers - AInvest
Abbott's Q2 Diabetes Care Sales Rise 19.6%: What's Backing It? - Yahoo Finance
Abbott Laboratories' (NYSE:ABT) Earnings Are Of Questionable Quality - Yahoo Finance
Arterial Stents Market Surge to 2035: Growth Driven by Abbott, Boston Scientific, BIOTRONIK & Biosensors - openPR.com
Medical Devices & SuppliesDiversified Stocks Q2 Highlights: Abbott Laboratories (NYSE:ABT) - Yahoo Finance
Abbott Laboratories (NYSE:ABT) Is a Favorite Amongst Institutional Investors Who Own 80% - 富途牛牛
What institutional investors are buying Abbott Laboratories stockOutstanding trading profits - Jammu Links News
What is the dividend policy of Abbott Laboratories stockFree Stock Chart Pattern Guide - Jammu Links News
Is it the right time to buy Abbott Laboratories stockTremendous wealth creation - Jammu Links News
How does Abbott Laboratories compare to its industry peersMaximize portfolio growth with professional advice - Jammu Links News
Abbott Laboratories Stock Analysis and ForecastCapitalize on momentum-driven opportunities - Jammu Links News
When is Abbott Laboratories stock expected to show significant growthConsistent high-performance stocks - jammulinksnews.com
UBS Shrugs Abbott Laboratories’ (ABT) Diagnostic Weakness Affirms ‘Buy’ Rating - MSN
RECKITT (RBGLY) URGENT DEADLINE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Reckitt Benckiser Group plc and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Abbott Laboratories Second Quarter 2025 Earnings: EPS Beats Expectations - simplywall.st
Stock Analysis | Abbott Laboratories OutlookMixed Signals Amid Strong Fundamentals and Technical Uncertainty - AInvest
Similac NEC Lawsuit: 2025 Updates & List of Affected Formulas - Drugwatch.com
What makes Abbott Laboratories stock price move sharplyPotential Breakout Stock List Published This Week - metal.it
Abbott Laboratories Shares Drop 1.84 as Analysts Clash on Value Amid $850M Volume 155th in Market Activity - AInvest
How volatile is Abbott Laboratories stock compared to the marketMarket Forecast Signals For Fast Growth - Jammu Links News
Estimating The Fair Value Of Abbott Laboratories (NYSE:ABT) - Yahoo Finance
Why Abbott Laboratories (ABT) Remains a Buy Despite Diagnostic Segment Weakness - AInvest
Abbott Laboratories 2025 Q2 Earnings Strong Performance as Net Income Climbs 36.6% - AInvest
Biotechnology Market is evolving rapidly Through 2025 To 2032 | Abbott Laboratories, Amgen Inc., GlaxoSmithKline - openPR.com
Abbott Gains 1.31% Amid 140th Trading Volume Rank as Analysts Weigh Diagnostic Sector Growth and Competitive Risks - AInvest
Meal Replacement Market Is Booming Worldwide 2025-2032 | Abbott - openPR.com
Paul MacDonald's Top Picks: Stryker, Abbott Labs & Elevance Health - BNN Bloomberg
Human Papilloma Virus Testing Market Research Report 2025-2033 Featuring Abbott Laboratories, BioMerieux, Bio-Rad Laboratories, Epigenomics, Siemens Healthineers, Hologic, Qiagen, F. Hoffmann-La Roche - Yahoo Finance
RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT) - MSN
2nd Abbott Baby Formula Bellwether Falls Before Trial - Law360
Does Abbott Laboratories stock perform well during market downturnsBuild a winning investment strategy today - jammulinksnews.com
Leerink Partners Decreases PT on Abbott Laboratories (ABT) to $136 From $143, Maintains a Hold Rating - Insider Monkey
Abbott Laboratories' Q2 Earnings Report Presents Mixed Picture, Leerink Partners Decreases PT to $136, Maintains Hold Rating - AInvest
RBC Capital Bullish on Abbott Laboratories, Raises Price Target to $147. - AInvest
How does Abbott Laboratories generate profit in a changing economyMaximize your returns with portfolio optimization - jammulinksnews.com
Abbott Laboratories Azioni (ABT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):